Post by iOMEDICO

1,119 followers

+++ ๐—ถ๐—ข๐— ๐—˜๐——๐—œ๐—–๐—ข ๐—ฎ๐˜ ๐—–๐—ง๐—ฆ๐—ฆ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ: ๐—ฅ๐—ช๐—— ๐˜๐—ผ ๐—ข๐—ฝ๐˜๐—ถ๐—บ๐—ถ๐˜‡๐—ฒ ๐——๐—ฟ๐˜‚๐—ด ๐——๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜ ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† +++ ย  Today, Michael Prรถschel presented at the #CTSS2026 insights into the use of #RWD for Optimizing Drug Development in #Oncology. Key topics were: ย  - Improved Covariate Adjustment based on RWD - Using External Control Arms (#ECA) - The regulatory landscape for RWD - RWD for the Joint Clinical Assessment (#JCA) - Importance of RWD being Fit-for-Purpose ย  At iOMEDICO we are 100% dedicated to Oncology and Hematology. With multiple regulatory grade clinical registries we help accelerate clinical development and market access. ย  #RealWorldData #realworldevidence #tumorregistry #ExternalControlArms #ClinicalResearch #iOMEDICO #CRO

Post contentPost contentPost contentPost contentPost contentPost content